Cargando…

Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients

Recent studies have shown that the cytochrome P450 (CYP) 3A phenotype marker 4β‐hydroxycholesterol/cholesterol (4βOHC/C) ratio is negatively correlated with body weight in healthy volunteers, and that obese patients have lower 4βOHC levels than healthy controls. However, 4βOHC/C ratio in underweight...

Descripción completa

Detalles Bibliográficos
Autores principales: Hole, Kristine, Heiberg, Petra L., Gjestad, Caroline, Mehus, Lise L., Rø, Øyvind, Molden, Espen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134200/
https://www.ncbi.nlm.nih.gov/pubmed/30214813
http://dx.doi.org/10.1002/prp2.430
_version_ 1783354634778181632
author Hole, Kristine
Heiberg, Petra L.
Gjestad, Caroline
Mehus, Lise L.
Rø, Øyvind
Molden, Espen
author_facet Hole, Kristine
Heiberg, Petra L.
Gjestad, Caroline
Mehus, Lise L.
Rø, Øyvind
Molden, Espen
author_sort Hole, Kristine
collection PubMed
description Recent studies have shown that the cytochrome P450 (CYP) 3A phenotype marker 4β‐hydroxycholesterol/cholesterol (4βOHC/C) ratio is negatively correlated with body weight in healthy volunteers, and that obese patients have lower 4βOHC levels than healthy controls. However, 4βOHC/C ratio in underweight patients has yet to be reported. The aim of this study was to examine potential differences in CYP3A activity between underweight patients with anorexia nervosa and normal‐weight volunteers by measuring plasma 4βOHC/C ratio. Furthermore, we wished to describe any association between body mass index (BMI) and 4βOHC/C ratio in underweight patients. A total of 20 underweight patients and 16 normal‐weight volunteers were included in the study, all females. Underweight patients had a median 4βOHC/C ratio (molar ratio × 10(−5)) of 2.52 (range, 0.90–11.3) compared to 1.29 (0.56–2.09) in normal‐weight subjects (Mann‐Whitney P = 0.0005). 4βOHC/C ratio was negatively correlated with BMI in underweight patients (r = −0.56, P = 0.011), and in the whole study population (r = −0.67, P < 0.0001). This suggests that the negative correlation between 4βOHC/C and BMI, which has previously been reported between 4βOHC/C and body weight in healthy volunteers, extends to underweight patients. The findings indicate that CYP3A activity increases with decreasing BMI, resulting in higher CYP3A activity in underweight patients compared to normal‐weight subjects. The potential clinical relevance of this needs to be studied further by comparing pharmacokinetics of drugs subjected to CYP3A‐mediated metabolism in underweight vs. normal‐weight individuals.
format Online
Article
Text
id pubmed-6134200
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61342002018-09-13 Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients Hole, Kristine Heiberg, Petra L. Gjestad, Caroline Mehus, Lise L. Rø, Øyvind Molden, Espen Pharmacol Res Perspect Original Articles Recent studies have shown that the cytochrome P450 (CYP) 3A phenotype marker 4β‐hydroxycholesterol/cholesterol (4βOHC/C) ratio is negatively correlated with body weight in healthy volunteers, and that obese patients have lower 4βOHC levels than healthy controls. However, 4βOHC/C ratio in underweight patients has yet to be reported. The aim of this study was to examine potential differences in CYP3A activity between underweight patients with anorexia nervosa and normal‐weight volunteers by measuring plasma 4βOHC/C ratio. Furthermore, we wished to describe any association between body mass index (BMI) and 4βOHC/C ratio in underweight patients. A total of 20 underweight patients and 16 normal‐weight volunteers were included in the study, all females. Underweight patients had a median 4βOHC/C ratio (molar ratio × 10(−5)) of 2.52 (range, 0.90–11.3) compared to 1.29 (0.56–2.09) in normal‐weight subjects (Mann‐Whitney P = 0.0005). 4βOHC/C ratio was negatively correlated with BMI in underweight patients (r = −0.56, P = 0.011), and in the whole study population (r = −0.67, P < 0.0001). This suggests that the negative correlation between 4βOHC/C and BMI, which has previously been reported between 4βOHC/C and body weight in healthy volunteers, extends to underweight patients. The findings indicate that CYP3A activity increases with decreasing BMI, resulting in higher CYP3A activity in underweight patients compared to normal‐weight subjects. The potential clinical relevance of this needs to be studied further by comparing pharmacokinetics of drugs subjected to CYP3A‐mediated metabolism in underweight vs. normal‐weight individuals. John Wiley and Sons Inc. 2018-09-11 /pmc/articles/PMC6134200/ /pubmed/30214813 http://dx.doi.org/10.1002/prp2.430 Text en © 2018 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Hole, Kristine
Heiberg, Petra L.
Gjestad, Caroline
Mehus, Lise L.
Rø, Øyvind
Molden, Espen
Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
title Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
title_full Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
title_fullStr Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
title_full_unstemmed Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
title_short Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
title_sort elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134200/
https://www.ncbi.nlm.nih.gov/pubmed/30214813
http://dx.doi.org/10.1002/prp2.430
work_keys_str_mv AT holekristine elevated4bhydroxycholesterolcholesterolratioinanorexianervosapatients
AT heibergpetral elevated4bhydroxycholesterolcholesterolratioinanorexianervosapatients
AT gjestadcaroline elevated4bhydroxycholesterolcholesterolratioinanorexianervosapatients
AT mehuslisel elevated4bhydroxycholesterolcholesterolratioinanorexianervosapatients
AT røøyvind elevated4bhydroxycholesterolcholesterolratioinanorexianervosapatients
AT moldenespen elevated4bhydroxycholesterolcholesterolratioinanorexianervosapatients